Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-01 · accession 0001104659-25-009284 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-02-01 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | — | +4,513 | 5,485 | +464% | — |
| D | 2025-02-04 | 2025-02-04 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $59.43 | -1,447 | 4,038 | -26% | -$86.0K |
| D | 2025-02-04 | 2025-02-01 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $0.00 | -4,513 | 9,024 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-01 | M | A | 4,513 | — | 5,485 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| 2 | Common | Common Stock | 2025-02-04 | S | D | 1,447 | $59.43 | 4,038 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2025-02-01 | M | D | 4,513 | $0.00 | 9,024 | D | — · — to — | 4,513 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F3) The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. |